Stick With the Intra-Cellular Rally for Another 25% Upside, Says Analyst

In the biotech world, positive clinical data readouts can be the spark that ignites the flame. Case in point: Intra-Cellular Therapies (ITCI) shares skyrocketed over 70% in Wednesday’s trading session, following positive results from a Phase 3 trial evaluating 42mg lumateperone (Caplyta) in patients with bipolar depression (BPD).The Caplyta arm of the trial was statistically significant on both the primary endpoint of change in total MADRS score and in the key secondary endpoint of CGI-BP-S Depression Score. To this end, ITCI is set to file an sNDA in late 2020 or early 2021.Writing for SVB Leerink, analyst Marc Goodman likes …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.